Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Estradiol/estradiol enanthate
Другие языки:

    Estradiol/estradiol enanthate

    Подписчиков: 0, рейтинг: 0
    Estradiol/estradiol enanthate
    Estradiol.svg
    Estradiol enanthate.png
    Estradiol (top) and
    estradiol enanthate (bottom)
    Combination of
    Estradiol Estrogen
    Estradiol enanthate Estrogen
    Clinical data
    Other names E2/E2-EN; E2/EEn
    Routes of
    administration    		 Intramuscular injection

    Estradiol/estradiol enanthate (E2/E2-EN) is an injectable combination formulation of estradiol (E2), a short-acting estrogen, and estradiol enanthate (E2-EN), a long-acting estrogen, which was developed by Boehringer around 1960 for potential medical use but was never marketed. It contained 1 mg E2 and 9 mg E2-EN in oil solution and was intended for administration by intramuscular injection.

    A single intramuscular injection of E2/E2-EN (1 mg/9 mg) has been found to result in a 10-fold increase in estradiol excretion on the 2nd day post-injection (due to the 1 mg short-acting E2 component). Following this, estradiol excretion remained above the menstrual-cycle average for 10 days post-injection and did not return to baseline until the 24th day post-injection (due to the 9 mg long-acting E2-EN component).

    E2/E2-EN is similar to estradiol benzoate/estradiol phenylpropionate (brand name Dimenformon Prolongatum), another injectable combination medication of a shorter-acting estrogen (2.5 mg) and a longer-acting estrogen (10 mg). In contrast to E2/E2-EN however, estradiol benzoate/estradiol phenylpropionate was marketed for medical use.

    See also




    Новое сообщение